Epizyme, Inc. - Common Stock (NQ:EPZM)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 11, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Epizyme, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck ↗

August 19, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline ↗

August 18, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business ↗

August 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...

Via Benzinga

Recap: Epizyme Q2 Earnings ↗

August 09, 2021

Shares of Epizyme (NASDAQ:EPZM) moved higher by 13.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 8.62% year...

Via Benzinga

Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal ↗

August 14, 2021

Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to...

Via Talk Markets

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts ↗

August 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (...

Via Benzinga

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗

July 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...

Via Benzinga

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO ↗

August 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (...

Via Benzinga

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗

August 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...

Via Benzinga

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering ↗

August 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,...

Via Benzinga

68 Biggest Movers From Yesterday ↗

August 10, 2021

Gainers Golden Nugget Online Gaming, Inc. (NASDAQ: GNOG) shares climbed 50.8% to close at $18.50 on Monday after the company and DraftKings announced they entered into a...

Via Benzinga

Epizyme, inc (EPZM) Q2 2021 Earnings Call Transcript ↗

August 09, 2021

EPZM earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Why Epizyme Is Getting Crushed Today ↗

August 09, 2021

It's uncomfortable when a company delivers an earnings miss and announces a CEO's departure on the same day.

Via The Motley Fool

Topics Earnings

Stocks That Hit 52-Week Lows On Monday ↗

August 09, 2021

Before 10 a.m. ET Monday, 63 stocks made new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was PACCAR (NASDAQ:PCAR)....

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 09, 2021

Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 30.38% to $2.36 during Monday's pre-market session. The company's market cap stands at $61.9 million. The...

Via Benzinga

Epizyme Announces CEO Succession

August 09, 2021

From Epizyme, Inc.

Via Business Wire

Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update

August 09, 2021

From Epizyme, Inc.

Via Business Wire

20 Stocks Moving in Monday's Pre-Market Session ↗

August 09, 2021

Gainers Windtree Therapeutics, Inc. (NASDAQ: WINT) shares rose 55.8% to $2.82 in pre-market trading after dropping over 10% on Friday. The company recently reported a wider loss...

Via Benzinga

Epizyme Stock Gains On Potential $310M Pact With HUTCHMED For Cancer-Focused Tazverik In Greater China ↗

August 09, 2021

Epizyme Inc (NASDAQ: EPZM) and HUTCHMED (China) Limited (NASDAQ: HCM) have collaborated to research, develop, manufacture, and commercialize Tazverik (...

Via Benzinga

Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China

August 08, 2021

From Epizyme, Inc.

Via Business Wire

Epizyme Announces Date of Second Quarter 2021 Financial Results

August 03, 2021

From Epizyme, Inc.

Via Business Wire

The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings ↗

August 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts ↗

July 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI...

Via Benzinga

Why Epizyme Stock Is Falling This Week ↗

July 02, 2021

The cancer drug developer's CFO will soon exit the company.

Via The Motley Fool

The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO ↗

June 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,...

Via Benzinga

Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients

June 16, 2021

From Epizyme, Inc.

Via Business Wire

Epizyme's Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models ↗

June 14, 2021

Epizyme Inc (NASDAQ: EPZM) has reported positive data from mouse studies for potential first-in-class therapy, EPZ-719, that targets the enzyme SETD2. The...

Via Benzinga

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗

May 31, 2021

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...

Via Benzinga

Epizyme to Participate in Jefferies Virtual Healthcare Conference

May 25, 2021

From Epizyme, Inc.

Via Business Wire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.